Evidence map›Paper›PMID 27854147›Full record

ArticlemAbs2017

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.

Melissa L Geddie, Neeraj Kohli, Dmitri B Kirpotin, Maja Razlog, Yang Jiao, Tad Kornaga, Rachel Rennard, Lihui Xu, Birgit Schoerberl, James D Marks and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Toward Drug-Like Multispecific Antibodies by Design.International journal of molecular sciences · 2020
    Review
  7. Review
  8. Targeting EphA2 in cancer.Journal of hematology & oncology · 2020
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Melissa L Geddiea Merrimack, Inc. , Cambridge , MA , USA.
Neeraj Kohlia Merrimack, Inc. , Cambridge , MA , USA.
Dmitri B Kirpotina Merrimack, Inc. , Cambridge , MA , USA.
Maja Razloga Merrimack, Inc. , Cambridge , MA , USA.
Yang Jiaoa Merrimack, Inc. , Cambridge , MA , USA.
Tad Kornagaa Merrimack, Inc. , Cambridge , MA , USA.
Rachel Rennarda Merrimack, Inc. , Cambridge , MA , USA.
Lihui Xua Merrimack, Inc. , Cambridge , MA , USA.
Birgit Schoerberla Merrimack, Inc. , Cambridge , MA , USA.
James D Marksa Merrimack, Inc. , Cambridge , MA , USA.
Daryl C Drummonda Merrimack, Inc. , Cambridge , MA , USA.
Alexey A Lugovskoya Merrimack, Inc. , Cambridge , MA , USA.
Merrimack Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-targeted nanoparticles have great promise as anti-cancer drugs; however, substantial developmental challenges of antibody modules prevent many candidates from reaching the clinic. Here, we describe a robust strategy for developing an EphA2-targeting antibody fragment for immunoliposomal drug delivery. A highly bioactive single-chain variable fragment (scFv) was engineered to overcome developmental liabilities, including low thermostability and weak binding to affinity purification resins. Improved thermostability was achieved by modifying the framework of the scFv, and complementarity-determining region (CDR)-H2 was modified to increase binding to protein A resins. The results of our engineering campaigns demonstrate that it is possible, using focused design strategies, to rapidly improve the stability and manufacturing characteristics of an antibody fragment for use as a component of a novel therapeutic construct.

Indexed as

NanoparticlesAnimalsDrug Delivery SystemsEphrin-A2HumansImmunoconjugatesImmunoglobulin Variable RegionProtein EngineeringProtein StabilityReceptor, EphA2Single-Chain AntibodiesEPHA2 protein, humanEphrin-A2ImmunoconjugatesImmunoglobulin Variable RegionReceptor, EphA2Single-Chain AntibodiesAntibody-drug conjugateantibody engineeringantibody fragmentdevelopabilityliposomemanufacturabilityprotein A bindingstability

Identifiers

PMID27854147
PMCPMC5240644
OpenAlexW2554756905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.